Filing Flows › Inhibrx Biosciences (INBX) › Q2 2025 › vs Q2 2024
Inhibrx Biosciences (INBX) Q2 2025 vs Q2 2024 (year over year)
Inhibrx Biosciences's revenue rose $1.2M (13×) from $100K in Q2 2024 to $1.3M in Q2 2025.
Inhibrx Biosciences, Q2 2025: revenue $1.3M (13× year over year), net loss $28.7M, operating cash flow −$30.0M. The chart draws each line against Q2 2024, the increases inside each band.
Every line
| Line | Q2 2025 | Q2 2024 | Change | % |
|---|---|---|---|---|
| Revenue | $1.3M | $100K | $1.2M | 13× |
| Net loss | $28.7M | −$1.9B | $1.9B | — |
| Costs & expenses | $30.0M | $2.0B | −$2.0B | -99% |
| Operating costs | $28.7M | $161M | −$132M | -82% |
| Interest & other, net | $1.3M | −$2.0B | $2.0B | — |
| Income tax | $2K | $2K | $0 | 0% |
| Research & development | $22.3M | $67.6M | −$45.4M | -67% |
| General & admin | $6.4M | $93.4M | −$86.9M | -93% |
| Operating cash sources | $33.4M | $104M | −$70.6M | -68% |
| Depreciation & amortization | $662K | $475K | $187K | +39% |
| Share-based compensation | $2.8M | $46.2M | −$43.4M | -94% |
| Cash used in operations | $30.0M | $57.4M | −$27.4M | -48% |
| Net loss absorbed | $28.7M | −$1.9B | $1.9B | — |
| Working capital & other | $4.7M | $2.0B | −$2.0B | -100% |
Questions
How much did Inhibrx Biosciences's revenue grow year over year in Q2 2025?
Inhibrx Biosciences's revenue rose $1.2M (13×) from $100K in Q2 2024 to $1.3M in Q2 2025.